OPTHEA LTD (F:UKJ) — Market Cap & Net Worth
Market Cap & Net Worth: OPTHEA LTD (UKJ)
OPTHEA LTD (F:UKJ) has a market capitalization of $437.75 Million (€374.43 Million) as of May 2, 2026. Listed on the F stock exchange, this Germany-based company holds position #13237 globally and #1366 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying OPTHEA LTD's stock price €0.32 by its total outstanding shares 1367978173 (1.37 Billion).
OPTHEA LTD Market Cap History: 2017 to 2026
OPTHEA LTD's market capitalization history from 2017 to 2026. Data shows change from $714.89 Million to $511.78 Million (-8.77% CAGR).
OPTHEA LTD Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how OPTHEA LTD's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of UKJ by Market Capitalization
Companies near OPTHEA LTD in the global market cap rankings as of May 2, 2026.
Key companies related to OPTHEA LTD by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
OPTHEA LTD Historical Marketcap From 2017 to 2026
Between 2017 and today, OPTHEA LTD's market cap moved from $714.89 Million to $ 511.78 Million, with a yearly change of -8.77%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €511.78 Million | 0.00% |
| 2025 | €511.78 Million | -31.33% |
| 2024 | €745.28 Million | +44.72% |
| 2023 | €514.98 Million | -41.45% |
| 2022 | €879.62 Million | -23.08% |
| 2021 | €1.14 Billion | -35.00% |
| 2020 | €1.76 Billion | -41.49% |
| 2019 | €3.01 Billion | +469.70% |
| 2018 | €527.77 Million | -26.17% |
| 2017 | €714.89 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of OPTHEA LTD was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $437.75 Million USD |
| MoneyControl | $437.75 Million USD |
| MarketWatch | $437.75 Million USD |
| marketcap.company | $437.75 Million USD |
| Reuters | $437.75 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About OPTHEA LTD
Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME).… Read more